This is an interventional, multi-center, randomized study. Adults with confirmed covid-19disease not more than 10 days before enrollment date will be recruited (n=1000). Patientsin same condition who get treated with standard of care will be randomly assigned to thecontrol group (n=1000), and patients in same condition who get treated with standard ofcare will be randomly assigned to the placebo group (n=1000). The investigators analyzethe effect of Xagrotin, and also investigate impact of different characteristics forinstance gender, age, duration of disease, smoking habits and concomitant diseases on theoutcome.
An interventional, multi-center, randomized study that will performe in an outpatient
setting (n=1000). Adults with confirmed covid-19 disease not more than 10 days before
enrollment date will be recruited. Patients in same condition who had treated with
standard of care will randomly assign to the control group (n=1000), and patients in same
condition who get treated with standard of care will be randomly assigned to the placebo
group (n=1000). The investigators analyze the effect of Xagrotin, and also investigate
impact of different characteristics for instance gender, age, duration of disease,
smoking habits and concomitant diseases on the outcome. Adverse events will be
registered.
Drug: Xagrotin
A herbal compound
Drug: Green tea
Normal green tea
Inclusion Criteria:
- Age 18 or higher
- Newly diagnosed (no longer than 10 days)
- PCR or clinically confirmed Covid-19
Exclusion Criteria:
- Coronavirus patients admitted to medical centers for hospitalization and receive
medical treatment and necessary care in medical centers
Directorate of health of Sulaimani, Iraq -KRG
Sulaymaniyah, Iraq
Dana Omer, PhD
+9647701586707
danaomar1979@gmail.com
Not Provided